JP2005532393A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005532393A5 JP2005532393A5 JP2004519718A JP2004519718A JP2005532393A5 JP 2005532393 A5 JP2005532393 A5 JP 2005532393A5 JP 2004519718 A JP2004519718 A JP 2004519718A JP 2004519718 A JP2004519718 A JP 2004519718A JP 2005532393 A5 JP2005532393 A5 JP 2005532393A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- tissue
- caged
- molecule
- modifying molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001519 tissue Anatomy 0.000 claims 20
- 235000018102 proteins Nutrition 0.000 claims 7
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 230000004075 alteration Effects 0.000 claims 4
- -1 o-nitrobenzyl Chemical group 0.000 claims 4
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 210000004379 membrane Anatomy 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 210000001775 bruch membrane Anatomy 0.000 claims 2
- 230000007423 decrease Effects 0.000 claims 2
- 238000009792 diffusion process Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000002961 echo contrast media Substances 0.000 claims 2
- 239000007850 fluorescent dye Substances 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 238000012014 optical coherence tomography Methods 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 102000005600 Cathepsins Human genes 0.000 claims 1
- 108010084457 Cathepsins Proteins 0.000 claims 1
- 229920002101 Chitin Polymers 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 108090001060 Lipase Proteins 0.000 claims 1
- 102000004882 Lipase Human genes 0.000 claims 1
- 239000004367 Lipase Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 1
- 208000022873 Ocular disease Diseases 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 102000012479 Serine Proteases Human genes 0.000 claims 1
- 108010022999 Serine Proteases Proteins 0.000 claims 1
- 208000027073 Stargardt disease Diseases 0.000 claims 1
- 108010055297 Sterol Esterase Proteins 0.000 claims 1
- 102000000019 Sterol Esterase Human genes 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical group [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229940009098 aspartate Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000003599 detergent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 201000006321 fundus dystrophy Diseases 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 235000019421 lipase Nutrition 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000000704 physical effect Effects 0.000 claims 1
- 208000027653 severe early-childhood-onset retinal dystrophy Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
- 230000004382 visual function Effects 0.000 claims 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39350502P | 2002-07-02 | 2002-07-02 | |
| PCT/US2003/020672 WO2004004757A1 (en) | 2002-07-02 | 2003-07-01 | Treatment for eye disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005532393A JP2005532393A (ja) | 2005-10-27 |
| JP2005532393A5 true JP2005532393A5 (enExample) | 2006-07-13 |
Family
ID=30115595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004519718A Pending JP2005532393A (ja) | 2002-07-02 | 2003-07-01 | 眼の障害についての処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7381404B2 (enExample) |
| EP (1) | EP1539222A1 (enExample) |
| JP (1) | JP2005532393A (enExample) |
| CN (1) | CN1678342A (enExample) |
| CA (1) | CA2491128A1 (enExample) |
| WO (1) | WO2004004757A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1539222A1 (en) * | 2002-07-02 | 2005-06-15 | The Regents Of The University Of California | Treatment for eye disorder |
| CN1980651A (zh) * | 2004-05-07 | 2007-06-13 | 加州大学评议会 | 近视的治疗 |
| US7654540B2 (en) * | 2004-06-18 | 2010-02-02 | Bose Corporation | Electromechanical transducing |
| WO2006021040A2 (en) * | 2004-08-27 | 2006-03-02 | Ellex Medical Pty Ltd | Selective ophthalmic laser treatment |
| JP2006195240A (ja) * | 2005-01-14 | 2006-07-27 | Fuji Photo Film Co Ltd | 断層画像化装置 |
| US7668342B2 (en) | 2005-09-09 | 2010-02-23 | Carl Zeiss Meditec, Inc. | Method of bioimage data processing for revealing more meaningful anatomic features of diseased tissues |
| US7768652B2 (en) * | 2006-03-16 | 2010-08-03 | Carl Zeiss Meditec, Inc. | Methods for mapping tissue with optical coherence tomography data |
| JP2009539508A (ja) * | 2006-06-15 | 2009-11-19 | シーガル アイピー ピーティーワイ リミテッド | 送達システム及び方法 |
| DE102006030382A1 (de) * | 2006-06-29 | 2008-01-03 | Carl Zeiss Meditec Ag | Verfahren und Vorrichtung zur optischen Detektion am Auge |
| AT504159A1 (de) * | 2006-08-16 | 2008-03-15 | Marlyn Nutraceuticals Inc | Verwendung von proteasen |
| US8043235B2 (en) * | 2006-08-22 | 2011-10-25 | Schwartz Donald N | Ultrasonic treatment of glaucoma |
| US8562595B2 (en) | 2006-10-25 | 2013-10-22 | Ellex R&D Pty Ltd | Retinal regeneration |
| US8795191B2 (en) * | 2007-02-15 | 2014-08-05 | The Uab Research Foundation | Photobleaching method |
| AU2008255642B2 (en) * | 2007-05-30 | 2013-03-07 | Alpharet Pty Ltd | Retinal rejuvenation laser |
| WO2010004365A1 (en) | 2008-07-10 | 2010-01-14 | Ecole Polytechnique Federale De Lausanne (Epfl) | Functional optical coherent imaging |
| KR101018785B1 (ko) * | 2008-11-28 | 2011-03-03 | 삼성전기주식회사 | 전자기 밴드갭 구조물 및 회로 기판 |
| US8609729B2 (en) * | 2009-04-15 | 2013-12-17 | Sucampo Ag | Method for treating macular degeneration |
| US9226654B2 (en) | 2011-04-29 | 2016-01-05 | Carl Zeiss Meditec, Inc. | Systems and methods for automated classification of abnormalities in optical coherence tomography images of the eye |
| CA2909914C (en) | 2012-04-27 | 2018-05-01 | Aimago S.A. | Optical coherent imaging medical device |
| JP6023883B2 (ja) * | 2012-07-10 | 2016-11-09 | アイマゴ ソシエテ アノニムＡｉｍａｇｏ Ｓ．Ａ． | 灌流評価マルチモダリティ光学医用デバイス |
| CN103705551A (zh) * | 2013-12-02 | 2014-04-09 | 黄丽娜 | 一种新型白蒺藜皂苷玻璃体腔注射给药系统及其应用 |
| CN103656621A (zh) * | 2013-12-02 | 2014-03-26 | 黄丽娜 | 一种新型鼠神经生长因子玻璃体腔注射给药系统及其应用 |
| CN103877430B (zh) * | 2014-04-20 | 2016-04-20 | 赵华 | 一种治疗黄斑变性的药物及制备方法 |
| US10169862B2 (en) | 2015-05-07 | 2019-01-01 | Novadaq Technologies ULC | Methods and systems for laser speckle imaging of tissue using a color image sensor |
| US11273072B2 (en) | 2017-01-13 | 2022-03-15 | Gyroscope Therapeutics Limited | Suprachoroidal injection device |
| ES2965670T3 (es) * | 2017-02-09 | 2024-04-16 | Altregen Co Ltd | Composición que comprende extracto compuesto de ginseng/ginseng rojo y pepino de mar como ingrediente eficaz para prevenir o tratar la enfermedad relacionada con la hipofunción de la membrana de Bruch |
| EP3637069B1 (en) | 2017-06-08 | 2024-07-03 | Ushio Denki Kabushiki Kaisha | Spectrum measurement method, spectrum measurement device, and broadband pulse light source unit |
| US20180360655A1 (en) * | 2017-06-16 | 2018-12-20 | Michael S. Berlin | Methods and systems for oct guided glaucoma surgery |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US91229A (en) * | 1869-06-15 | Improvement in feeding-device for machines for combing- cotton | ||
| US6A (en) * | 1836-08-10 | Thomas Blanchard | Machine for forming end pieces of plank blocks for ships | |
| US87985A (en) * | 1869-03-16 | Improved rotary metal-cotter | ||
| US138329A (en) * | 1873-04-29 | Improvement in wheel-plows | ||
| US220245A (en) * | 1879-10-07 | Improvement in provision-safes | ||
| US4944944A (en) * | 1987-11-19 | 1990-07-31 | Oklahoma Medical Research Foundation | Dietary compositions and methods using bile salt-activated lipase |
| US20030087985A1 (en) | 1990-10-15 | 2003-05-08 | Hubbell Jeffrey A. | Gels for encapsulation of biological materials |
| US5410016A (en) | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
| US5462990A (en) | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
| US5626863A (en) | 1992-02-28 | 1997-05-06 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
| US5573934A (en) | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
| US5468505A (en) | 1992-02-28 | 1995-11-21 | Board Of Regents, The University Of Texas System | Local delivery of fibrinolysis enhancing agents |
| WO1993017669A1 (en) | 1992-02-28 | 1993-09-16 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
| US20040138329A1 (en) | 1992-04-20 | 2004-07-15 | Board Of Regents Of The University Of Texas System | Gels for encapsulation of biological materials |
| US5310764A (en) | 1992-05-08 | 1994-05-10 | Steven Baranowitz | Treatment of age related macular degeneration with beta-carotene |
| US5800373A (en) | 1995-03-23 | 1998-09-01 | Focal, Inc. | Initiator priming for improved adherence of gels to substrates |
| US5458505A (en) * | 1994-02-03 | 1995-10-17 | Prager; Jay H. | Lamp cooling system |
| US5798349A (en) | 1994-03-14 | 1998-08-25 | The General Hospital Corporation | Use of green porphyrins to treat neovasculature in the eye |
| US5935942A (en) | 1994-12-14 | 1999-08-10 | Zeimer; Ran | Selective and non-invasive visualization or treatment of vasculature |
| EP0815177B1 (en) | 1995-03-23 | 2007-08-08 | Genzyme Corporation | Redox and photoinitiator systems for priming for improved adherence of gels to substrates |
| US6461640B1 (en) | 1995-12-08 | 2002-10-08 | Board Of Regents, The University Of Texas System | Local delivery of fibrinolysis enhancing agents |
| US5756541A (en) | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
| US6059828A (en) * | 1996-03-18 | 2000-05-09 | Peyman; Gholam A. | Macular indentor for use in the treatment of subretinal neovascular membranes |
| EP1019031A4 (en) | 1997-07-18 | 2003-02-05 | Infimed Inc | BIODEGRADABLE MACROMERS FOR THE REGULATED RELEASE OF BIOLOGICALLY ACTIVE SUBSTANCES |
| US6128525A (en) | 1997-07-29 | 2000-10-03 | Zeng; Haishan | Apparatus and method to monitor photodynamic therapy (PDT) |
| EP1027016A4 (en) | 1997-10-27 | 2006-03-08 | Univ California | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REFERRING RETINAL RIPPLE |
| US6472541B2 (en) | 1998-11-20 | 2002-10-29 | The Regents Of The University Of California | Protecting groups with increased photosensitivities |
| US6858229B1 (en) | 1999-04-26 | 2005-02-22 | California Institute Of Technology | In situ forming hydrogels |
| DE19920158A1 (de) * | 1999-04-29 | 2000-11-02 | Univ Schiller Jena | Verfahren und Anordnung zur Bestimmung von Fluorophoren an Objekten, insbesondere am lebenden Augenhintergrund |
| US6271233B1 (en) * | 1999-08-10 | 2001-08-07 | Ciba Vision Corporation | Method for treating ocular neovascular diseases |
| US6267954B1 (en) | 1999-11-24 | 2001-07-31 | Universite De Paris V Rene-Descartes | Intraocular transplantation of encapsulated cells |
| EP1267935A2 (en) | 2000-01-12 | 2003-01-02 | Light Sciences Corporation | Novel treatment for eye disease |
| US7011952B2 (en) * | 2000-02-22 | 2006-03-14 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
| US7291673B2 (en) | 2000-06-02 | 2007-11-06 | Eidgenossiche Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
| CA2468989A1 (en) | 2001-12-07 | 2003-06-19 | Daniel M. Schwartz | Treatment for age-related macular degeneration |
| EP1539222A1 (en) | 2002-07-02 | 2005-06-15 | The Regents Of The University Of California | Treatment for eye disorder |
| US20040199130A1 (en) * | 2003-04-03 | 2004-10-07 | Chornenky Victor I. | Apparatus and method for treatment of macular degeneration |
-
2003
- 2003-07-01 EP EP03763073A patent/EP1539222A1/en not_active Withdrawn
- 2003-07-01 US US10/611,013 patent/US7381404B2/en not_active Expired - Fee Related
- 2003-07-01 CA CA002491128A patent/CA2491128A1/en not_active Abandoned
- 2003-07-01 WO PCT/US2003/020672 patent/WO2004004757A1/en not_active Ceased
- 2003-07-01 CN CNA038208113A patent/CN1678342A/zh active Pending
- 2003-07-01 JP JP2004519718A patent/JP2005532393A/ja active Pending
-
2008
- 2008-05-23 US US12/126,100 patent/US8298521B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005532393A5 (enExample) | ||
| US8298521B2 (en) | Treatment for eye disorder | |
| Pandey et al. | Potential of stimuli-responsive in situ gel system for sustained ocular drug delivery: Recent progress and contemporary research | |
| Yoon et al. | Optogenetic inactivation of the subthalamic nucleus improves forelimb akinesia in a rat model of Parkinson disease | |
| Gao et al. | Targeted mRNA nanoparticles ameliorate blood–brain barrier disruption postischemic stroke by modulating microglia polarization | |
| Bastús et al. | Homogeneous conjugation of peptides onto gold nanoparticles enhances macrophage response | |
| ES2460578T3 (es) | Uso de EDTA+trometamina o de foto-potenciadores, asociados a la riboflavina, para la reticulación de la córnea en el tratamiento del queratocono o de otros trastornos ectásicos de la córnea | |
| Sano et al. | Differential effects of N-acetylcysteine on retinal degeneration in two mouse models of normal tension glaucoma | |
| Wang et al. | Light-induced Nrf2−/− mice as atrophic age-related macular degeneration model and treatment with nanoceria laden injectable hydrogel | |
| JP6703040B2 (ja) | 角膜創傷治癒および眼表面疾患のためのヒスタチン | |
| JP2007536272A (ja) | 近視の処置法 | |
| CN105056206A (zh) | 用于预防或治疗眼科病症的方法和组合物 | |
| CN1753683A (zh) | 预防和治疗不良眼部病症的眼用制剂 | |
| Pitha et al. | Targeted microglial attenuation through Dendrimer–Drug Conjugates improves Glaucoma neuroprotection | |
| JP2011515476A (ja) | 角膜上皮の透過性を向上させ、かつ、基質コラーゲン原線維網を不安定化させる方法 | |
| JP2005511576A (ja) | 眼球血管新生病を治療する方法 | |
| CN1671400A (zh) | 透明质酸组合物以及使用方法 | |
| ES2945740T3 (es) | Aplicaciones oculares de vesículas unidas a matriz (MBV) | |
| Bukhari et al. | Irrigation in endodontics: a review | |
| US20180094137A1 (en) | Compositions and methods for the delivery of drugs to the ocular surface by contact lenses | |
| Xu et al. | Red light‐triggered anti‐angiogenic and photodynamic combination therapy of age‐related macular degeneration | |
| CN1291897A (zh) | 无机亚硝酸盐和有机酸联合用作局部抗病毒组合物 | |
| TWI426082B (zh) | 癌症轉移的抑制 | |
| Salehi et al. | Absorption enhancer approach for protein delivery by various routes of administration: a rapid review | |
| Liu et al. | Smart nanocarriers for the treatment of retinal diseases |